Edition:
United Kingdom

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

59.19USD
9:01pm BST
Change (% chg)

$-0.69 (-1.15%)
Prev Close
$59.88
Open
$59.95
Day's High
$59.95
Day's Low
$58.82
Volume
1,995,088
Avg. Vol
1,914,484
52-wk High
$64.60
52-wk Low
$42.88

Chart for

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.57
Market Cap(Mil.): $95,559.38
Shares Outstanding(Mil.): 1,737.44
Dividend: 0.26
Yield (%): 1.93

Financials

  ABT.N Industry Sector
P/E (TTM): 84.45 30.95 32.74
EPS (TTM): 0.65 -- --
ROI: 2.24 14.84 14.38
ROE: 4.07 16.34 16.07

Abbott sticks to earlier forecasts, disappoints investors

Abbott Laboratories' just beat expectations for first quarter profits and revenue on Wednesday but stuck to a full-year profit forecast some investors had expected would be raised, sending the healthcare company's shares lower.

18 Apr 2018

UPDATE 3-Abbott sticks to earlier forecasts, disappoints investors

* Analysts cite disappointment on whisper numbers among investors

18 Apr 2018

BRIEF-Abbott Q1 GAAP Earnings Per Share $0.23 From Continuing Operations

* Q1 GAAP EARNINGS PER SHARE $0.23 FROM CONTINUING OPERATIONS

18 Apr 2018

Abbott Labs' quarterly revenue rises 16.7 percent

April 18 Abbott Laboratories on Wednesday posted a 16.7 percent rise in quarterly revenue, helped by strong demand for its newer devices.

18 Apr 2018

BRIEF-Abbott Initiates Groundbreaking Study To Assess Superiority Of High-Resolution Imaging Versus Standard-Of Care Angiography In Treating Coronary Artery Disease

* RESOLUTION IMAGING RESULT IN LARGER VESSEL DIAMETERS Source text for Eikon: Further company coverage:

11 Apr 2018

RPT-UPDATE 1-Smith & Nephew picks new CEO who sold his last company

LONDON, April 4 Artificial hip and knee maker Smith & Nephew, a perennial target of takeover speculation, said on Wednesday it had appointed a new chief executive with a track record of deal-making.

04 Apr 2018

BRIEF-Abbott Initiates Trial To Evaluate Improved Survival And Outcomes With The Cardiomems Monitor

* ABBOTT INITIATES TRIAL TO EVALUATE IMPROVED SURVIVAL AND OUTCOMES WITH THE CARDIOMEMS MONITOR

29 Mar 2018

Abbott's Alere resolves U.S. diagnostic device probe for $33.2 mln

BOSTON, March 23 Alere Inc has agreed to pay $33.2 million to resolve claims it knowingly sold unreliable diagnostic testing devices to hospitals prior to its acquisition by Abbott Laboratories last year, the U.S. Justice Department said on Friday.

23 Mar 2018

BRIEF-Abbott's MitraClip Therapy Receives National Reimbursement In Japan To Treat Patients With Mitral Regurgitation

* ABBOTT'S MITRACLIP THERAPY RECEIVES NATIONAL REIMBURSEMENT IN JAPAN TO TREAT PATIENTS WITH MITRAL REGURGITATION

19 Mar 2018

BRIEF-Abbott Laboratories CEO Miles White's Total Compensation,Without Change In Pension Value Was $16.8 Mln V/s $17.4 Million In 2016

* ABBOTT LABORATORIES CEO MILES D. WHITE'S 2017 TOTAL COMPENSATION(TOTAL WITHOUT CHANGE IN PENSION VALUE) WAS $16.8 MILLION VERSUS $17.4 MILLION IN 2016 – SEC FILING‍​ Source text (http://bit.ly/2IwpJvl) Further company coverage: (Reuters.Brief@thomsonreuters.com)

16 Mar 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $126.66 -0.89
Pfizer Inc. (PFE.N) $36.63 +0.10
Novartis AG (NOVN.S) CHF76.08 -1.20
Merck & Co., Inc. (MRK.N) $58.83 +0.19
Sanofi SA (SASY.PA) €65.28 -0.32
AstraZeneca plc (AZN.L) 4,976.00 +20.50
GlaxoSmithKline plc (GSK.L) 1,430.00 +22.60
Eli Lilly And Co (LLY.N) $79.06 -0.69
Amgen, Inc. (AMGN.OQ) $171.56 -1.37
Boston Scientific Corporation (BSX.N) $28.84 -0.05

Earnings vs. Estimates